| Trial name | Arm I | Arm II |
| Alba 2004 | Arm I: AT= Doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 both on day 1. Cycles repeated every 21 days for 6 cycles. If prior anthracyclines: given 3 cycles of AT at above doses followed by 3 cycles of docetaxel 100 mg/m2 | Arm II: A→T= Doxorubicin 75 mg/m2 intravenously day 1 for 3 cycles followed by docetaxel 100 mg/m2 intravenously day 1 for 3 cycles. If prior anthracyclines given 2 cycles of doxorubicin 75 mg/m2 followed by 4 cycles of docetaxel 100 mg/m2. Cycles repeated every 21 days |
| Baker 1974 | Arm I: FCV= 5‐fluorouracil 7.5 mg/kg intravenously days 1‐5 plus cyclophosphamide 4 mg/kg intravenously days 1 to 5 plus vincristine 0.015 mg/kg intravenously days 1 and 8. Cycles repeated every 28 days until disease progression | Arm II: F→C→V= 5‐fluorouracil 15 mg/kg intravenously days 1 to 5 every 28 days until disease progression then cyclophosphamide 8 mg/kg intravenously days 1 to 5 every 28 days until disease progression then vincristine 0.02 mg/kg intravenously weekly until disease progression |
| Beslija 2006 | Arm I: XT= Capecitabine (Xeloda, X) 1250 mg/m2 twice daily orally from days 1 to 14 and docetaxel (Taxotere, T) 75 mg/m2 intravenously day 1. Cycle repeated every 21 days until disease progression | Arm II: T→X= Docetaxel 100 mg/m2 intravenously day 1 until disease progression then capecitabine 1250 mg/m2 twice daily orally from days 1 to 14 until disease progression. Cycles repeated every 21 days |
| Chlebowski 1989 | WCSG Arm I: CMFTP= Cyclophosphamide 2 mg/kg/day orally, plus 5‐fluorouracil 15 mg/kg every 2 weeks intravenously from day 1, plus methotrexate 30 mg/m2 every 2 weeks intravenously beginning on day 8, plus prednisone 0.5 mg/kg/day orally, plus triiodothyronine 0.005 mg daily. Cycle repeated until disease progression. SECSG Arm I: Cyclophosphamide 400 mg/m2 intravenously day 1 every 28 days, plus 5‐fluorouracil 400 mg/m2 intravenously day 1 and day 8 every 28 days, plus methotrexate 30 mg/m2 intravenously day 1 and day 8 every 28 days, plus vincristine 1 mg/m2 intravenously day 1 and day 8 every 28 days, plus prednisone 80mg orally daily from days 1 to 7 every 28 days. Cycle repeated until disease progression. or Cyclophosphamide 100 mg orally daily, plus 5‐fluorouracil 400 mg/m2 intravenously weekly, plus methotrexate 20 mg/m2 orally weekly, plus vincristine 1 mg/m2 intravenously weekly, plus prednisone 45 mg orally daily for 14 days, then 30 mg daily for 14 days then 15 mg daily for 28 days. Cycle repeated until disease progression | WCSG Arm II: F→C→TP→M= 5‐fluorouracil 15 mg/kg weekly intravenously from day 1 for a minimum of 4 weeks until disease progression then cyclophosphamide 2 mg/kg/day orally for a minimum of 4 weeks until disease progression then triiodothyronine 0.005 mg daily plus prednisone 0.5 mg/kg/day for a minimum of 6 weeks until disease progression then methotrexate 30 mg/m2 intravenously weekly for a minimum of 4 weeks SECSG Arm II: F→MC→V→P= 5‐fluorouracil 600 mg/m2 intravenously weekly until disease progression then methotrexate 20 mg/m2 orally biweekly until disease progression then cyclophosphamide 100 mg/m2 orally daily until disease progression then vincristine 1 mg/m2 intravenously weekly until disease progression then prednisone 45 mg orally daily for 14 days then 30 mg daily for 14 days then 15 mg daily for 30 days |
| Conte 2004 | Arm I: EP= Epirubicin 90 mg/m2 plus paclitaxel 200 mg/m2 intravenously day 1. Cycles repeated every 21 days for 8 cycles | Arm II: E→P= Epirubicin 120 mg/m2 intravenously day 1 for 4 cycles then paclitaxel 250 mg/m2 intravenously day 1 for 4 cycles. Cycles repeated every 21 days |
| Cresta 2003 | Arm I: AT= Doxorubicin 60 mg/m2 plus docetaxel 60 mg/m2 intravenously day. Cycles repeated every 21 days for 8 cycles | Arm II: A→T (sequential regimen)= Doxorubicin 75 mg/m2 intravenously on day 1 for 4 cycles followed by docetaxel 75 mg/m2 intravenously on day 1 for 4 cycles. Cycles repeated every 21 days. Maximum 8 cycles. Arm III: T then A (alternating regimen)= Docetaxel 100 mg/m2 intravenously on day 1 for 4 cycles alternating with doxorubicin 75 mg/m2 intravenously on day 1 for 4 cycles. Cycles repeated every 21 days. Maximum 8 cycles |
| Fountzilas 2001 | Arm I: P= Epirubicin 80 mg/m2 plus paclitaxel 175 mg/m2 intravenously day 1. Cycles repeated every 21 days for 6 cycles | Arm II: E→P Epirubicin 110 mg/m2 intravenously day 1 for 4 cycles followed by paclitaxel 225 mg/m2 intravenously day 1 for 4 cycles. Cycles repeated every 14 days with G‐CSF support (dose dense regimen) |
| Koroleva 2001 | Arm I: AT= Doxorubicin 50 mg/m2 plus docetaxel 75 mg/m2 intravenously day 1. Cycles repeated every 21 days for 8 cycles | Arm II: T→A= Docetaxel 100 mg/m2 intravenously day 1 for 4 cycles followed by doxorubicin 75 mg/m2 intravenously day 1 for 4 cycles. Cycles repeated every 21 days. Arm III: AT= Doxorubicin 60 mg/m2 plus docetaxel 60 mg/m2 intravenously day 1. Cycles repeated every 21 days for 8 cycles |
| Park 2010 | Arm I: GV= Gemcitabine 1,000 mg/m2 plus vinorelbine 25 mg/m2 intravenously days 1 and 8. Cycles repeated every 21 days until disease progression | Arm II: G→V= Gemcitabine 1,200 mg/m2 intravenously on days 1 and 8 until disease progression then vinorelbine 30 mg/m2 intravenously days 1 and 8 until disease progression. Cycles repeated every 21 days |
| Sledge 2003 | Arm I: AT= Doxorubicin 50 mg/m2 plus paclitaxel 150 mg/m2 over 24 hours intravenously day 1. Cycles repeated every 21 days until disease progression | Arm II: A (→P)= Doxorubicin 60 mg/m2 intravenously day 1 for a maximum of 8 cycles. If disease progressed crossed over to paclitaxel 175 mg/m2 intravenously over 24 hours on day 1. Cycles repeated every 21 days. Arm III: P (→A)= Paclitaxel 175 mg/m2 intravenously over 24 hours on day 1. If disease progressed crossed over to doxorubicin 60 mg/m2 intravenously day 1. Cycles repeated every 21 days |
| Soto 2006 | Arm I: XT= Capecitabine 825 mg/m2 twice daily orally from days 1 to 14 plus docetaxel 75 mg/m2 intravenously on day 1 until disease progression. Cycles repeated every 21 days | Arm II: X→T (docetaxel or paclitaxel)= Capecitabine 1250 mg/m2 twice daily orally days 1 to 14 until disease progression then docetaxel 100 mg/m2 or paclitaxel 175 mg/m2 intravenously on day 1 until disease progression. Cycles repeated every 21 days. Arm III: XP= Capecitabine 825 mg/m2 twice daily orally from days 1 to 14 plus paclitaxel 175 mg/m2 intravenously on day 1 until disease progression. Cycles repeated every 21 days |
| Tomova 2010 | Arm I: TG= Docetaxel 75 mg/m2 intravenously on day 1 plus gemcitabine 1,000 mg/m2 intravenously on days 1 and 8. Cycles repeated every 21 days for 8 cycles | Arm II: T→G= Docetaxel 100 mg/m2 intravenously on day 1 for 4 cycles followed by gemcitabine 1,250 mg/m2 intravenously on days 1 and 1 for 4 cycles. Cycles repeated every 21 days |
